Published • loading... • Updated
Understanding How ‘Biosimilar’ Drugs Can Expand Access and Affordability
- Biosimilars are highly similar versions of complex biologic medicines that provide the same clinical benefits and may expand access to advanced treatments.
- They are often less expensive than their reference biologics, offering patients more affordable treatment options.
- A JAMA analysis reported that biosimilars generated nearly $20 billion in savings during 2024.
- The U.S. FDA requires evidence that biosimilars have no clinically meaningful differences in safety, purity, or effectiveness, and research supports switching without reduced safety or effectiveness.
Insights by Ground AI
30 Articles
30 Articles
Understanding How ‘Biosimilar’ Drugs Can Expand Access and Affordability
(StatePoint) Biological drug products (biologics) — which can be made of sugars, proteins, living cells, tissues, or a combination of these — are providing new options for patients with conditions such as diabetes, arthritis, chronic bowel diseases, macular degeneration, and…
Coverage Details
Total News Sources30
Leaning Left5Leaning Right2Center20Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
L 19%
C 74%
Factuality
To view factuality data please Upgrade to Premium
